For nearly 50 years, Dar Aldawa has been a renowned pharmaceutical company that has led the way in the MENA region. With a proven history of attaining milestones, the company runs four production plants in Jordan and three in Algeria. Boasting cutting-edge manufacturing technologies, Dar Aldawa has positioned itself as a reputable player in the pharmaceutical industry
In addition, the company has received multiple global accreditations from several countries, which demonstrates its commitment to maintaining high international quality standards and confirms its reputation as a dependable and trustworthy pharmaceutical company across the globe.
Research
& Development
Sustaining Dar Aldawa’s growth over the long term is a function of our commitment to research and development and the results that this investment delivers. Our pharmaceutical development unit focuses on developing new forms to render high-quality affordable medicines accessible to patients.
We have in depth knowledge and hands on experience in the formulation and process development of various dosage forms including tablets (IR and MR), capsules, liquids, dry suspensions, suppositories, creams, ointments, gels, ophthalmic and nasal preparations. Our labs are equipped with modern instruments and equipment that enable us to develop and optimize various formulation designs and concepts.
The analytical research unit has the knowledge and expertise in analytical method development, validation, physiochemical characterization and stability studies. Since we began our research and development activities, we have filed investigational new drug applications and progressed multiple proprietary compounds into clinical and commercial development. In an industry that is technology-driven, Dar Aldawa’s Research & Development is working on new technologies and processes that complement existing product lines and achieve product life cycle management.
Licensing And Business
Development
Dar Aldawa is committed to delivering high quality and affordable medicines to patients. We are continuously increasing our portfolio through in-licensing opportunities, product development, acquisitions and strategic alliances that fit within our business units. We are always interested in hearing from companies who can offer opportunities in these areas.
